Best Reads Of The Week With Brianna Labuskes
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
The independent source for health policy research, polling, and news.
461 - 480 of 524 Results
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
The first-in-the-nation measure would empower Vermont to set up a wholesale program to import prescription drugs from Canada. But it still will have to get federal buy-in before it is operational.
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
The former secretary of the Department of Health and Human Services says the law eliminating penalties for most people who don’t have insurance coverage will hurt the insurance marketplaces.
Newsletter editor Brianna Labuskes, who reads everything on health care to compile our daily Morning Briefing, offers the best and most provocative stories for the weekend.
President Donald Trump’s upcoming speech on drug prices comes after months of public comments and debate about tackling the issue.
A look at the most consequential events that have reshaped the federal health law since President Donald Trump was inaugurated.
In this special episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Margot Sanger-Katz of The New York Times and Alice Ollstein of Talking Points Memo take a deep dive into the state of the federal health law, what happened in 2017 and the Affordable Care Act's viability going forward.
Critics say the Trump administration failed to properly vet Dr. Robert Redfield as they attribute a pattern of “ethically and morally questionable behavior” to him.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Joanne Kenen of Politico and Paige Winfield Cunningham of The Washington Post discuss the problems that are making congressional efforts to pass legislation to stabilize the individual insurance market a long shot.
The federal Centers for Medicare & Medicaid Services advised the state that its plan to offer state-based insurance plans falls short of the Obamacare rules and could result in penalties for insurers.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and new podcast panelist Anna Edney of Bloomberg News discuss this week’s spate of speeches by the leaders of the Department of Health and Human Services. They also discuss the slow progress on health legislation on Capitol Hill intended to fund the government and stabilize the individual insurance market. Plus, for extra credit, the panelists offer their favorite health policy stories of the week.
The HHS civil rights division refocuses on the rights of health care providers who have moral objections to treatments such as abortion or sterilization, alarming critics.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Stephanie Armour of The Wall Street Journal and Julie Appleby of Kaiser Health News discuss the Trump administration’s proposed regulation that would allow the expansion of short-term health insurance policies that do not comply with all the requirements of the Affordable Care Act. The panelists also talk about federal funding (or not) of public health research around guns.
Legislatures in blue and red states alike are considering proposals that would allow them to import prescription drugs from Canada.
Focus turns to whether the Trump administration will challenge Idaho’s move to allow such plans to be sold to individuals.
Many eyes are on the Trump administration to see how officials respond to Idaho’s approach to health insurance, which flouts some aspects of the Affordable Care Act.
A KHN data analysis finds that the door of opportunities connecting Capitol Hill, the federal government and the drug industry likely spins in Big Pharma’s favor.
For some federal health programs, a shuttered government means business as usual. But the congressional impasse over funding will hit others hard.
Allowing states to mandate that non-disabled Medicaid enrollees work as a condition for coverage would mark one of the biggest changes to the program since it began more than 50 years ago. A decision on the first of the state requests could come within days.
© 2026 KFF